ABN AMRO Bank N.V. Buys 5,658 Shares of Quest Diagnostics Incorporated $DGX

Key Points

• ABN AMRO Bank N.V. boosted its Quest Diagnostics stake by 6.4% in the first quarter, buying 5,658 additional shares and bringing its total to 94,640 shares worth about $18.7 million.
• Quest Diagnostics reported better-than-expected quarterly results, with EPS of $2.50 versus $2.37 expected and revenue of $2.90 billion, up 9.2% year over year. The company also reaffirmed guidance for FY 2026 EPS of 10.630-10.830.
• The company announced a quarterly dividend of $0.86 per share, payable July 22, implying an annualized dividend of $3.44 and a yield of 1.6%. Meanwhile, analysts currently view the stock as a “Moderate Buy” with a consensus price target of $216.58.

ABN AMRO Bank N.V. increased its stake in shares of Quest Diagnostics Incorporated (NYSE:DGX - Free Report) by 6.4% in the first quarter, according to the company in its most recent Form 13F filing with the SEC. The fund owned 94,640 shares of the medical research company's stock after acquiring an additional 5,658 shares during the quarter. ABN AMRO Bank N.V. owned about 0.09% of Quest Diagnostics worth $18,736,000 at the end of the most recent quarter.

Other institutional investors also recently bought and sold shares of the company. Norges Bank purchased a new stake in Quest Diagnostics in the 4th quarter worth $229,522,000. Boston Partners grew its position in shares of Quest Diagnostics by 32.8% during the third quarter. Boston Partners now owns 4,036,881 shares of the medical research company's stock valued at $767,978,000 after purchasing an additional 997,033 shares in the last quarter. EdgePoint Investment Group Inc. increased its holdings in shares of Quest Diagnostics by 66,757.0% in the third quarter. EdgePoint Investment Group Inc. now owns 849,752 shares of the medical research company's stock worth $161,946,000 after purchasing an additional 848,481 shares during the last quarter. UBS Group AG increased its holdings in shares of Quest Diagnostics by 67.8% in the fourth quarter. UBS Group AG now owns 1,114,451 shares of the medical research company's stock worth $193,391,000 after purchasing an additional 450,161 shares during the last quarter. Finally, Bank of America Corp DE lifted its position in shares of Quest Diagnostics by 36.3% in the second quarter. Bank of America Corp DE now owns 1,599,602 shares of the medical research company's stock worth $287,337,000 after buying an additional 426,399 shares in the last quarter. 88.06% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts recently commented on DGX shares. UBS Group increased their price target on Quest Diagnostics from $210.00 to $220.00 and gave the company a "neutral" rating in a research note on Wednesday, April 22nd. Evercore set a $225.00 price objective on Quest Diagnostics in a research note on Tuesday, April 21st. Weiss Ratings cut Quest Diagnostics from a "buy (b+)" rating to a "buy (b)" rating in a report on Wednesday. Wall Street Zen downgraded Quest Diagnostics from a "buy" rating to a "hold" rating in a research report on Sunday. Finally, Barclays raised their target price on shares of Quest Diagnostics from $225.00 to $230.00 and gave the company an "overweight" rating in a report on Wednesday, April 22nd. Seven analysts have rated the stock with a Buy rating and seven have issued a Hold rating to the stock. According to MarketBeat.com, the company presently has an average rating of "Moderate Buy" and a consensus price target of $216.58.

Insiders Place Their Bets

In other Quest Diagnostics news, CEO J. E. Davis sold 10,000 shares of the company's stock in a transaction on Monday, June 1st. The stock was sold at an average price of $194.14, for a total value of $1,941,400.00. Following the transaction, the chief executive officer owned 132,423 shares of the company's stock, valued at $25,708,601.22. This represents a 7.02% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, SVP Karthik Kuppusamy sold 8,147 shares of the company's stock in a transaction on Thursday, June 4th. The shares were sold at an average price of $200.00, for a total value of $1,629,400.00. Following the completion of the transaction, the senior vice president directly owned 13,510 shares in the company, valued at $2,702,000. This trade represents a 37.62% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. 0.88% of the stock is owned by insiders.

Quest Diagnostics Stock Performance

Shares of NYSE:DGX opened at $209.73 on Friday. The company has a current ratio of 1.18, a quick ratio of 1.08 and a debt-to-equity ratio of 0.67. Quest Diagnostics Incorporated has a 12 month low of $164.65 and a 12 month high of $213.50. The company has a market capitalization of $23.22 billion, a price-to-earnings ratio of 23.17, a PEG ratio of 2.50 and a beta of 0.59. The firm's 50-day moving average is $195.83 and its 200 day moving average is $192.79.

Quest Diagnostics (NYSE:DGX - Get Free Report) last announced its quarterly earnings data on Tuesday, April 21st. The medical research company reported $2.50 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.37 by $0.13. Quest Diagnostics had a net margin of 9.07% and a return on equity of 15.60%. The business had revenue of $2.90 billion during the quarter, compared to the consensus estimate of $2.83 billion. During the same quarter last year, the firm earned $1.94 earnings per share. The firm's quarterly revenue was up 9.2% compared to the same quarter last year. Quest Diagnostics has set its FY 2026 guidance at 10.630-10.830 EPS. Research analysts predict that Quest Diagnostics Incorporated will post 10.72 EPS for the current year.

Quest Diagnostics Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, July 22nd. Investors of record on Wednesday, July 8th will be paid a dividend of $0.86 per share. This represents a $3.44 dividend on an annualized basis and a dividend yield of 1.6%. The ex-dividend date of this dividend is Wednesday, July 8th. Quest Diagnostics's dividend payout ratio (DPR) is currently 38.01%.

Quest Diagnostics Profile

Quest Diagnostics NYSE: DGX is a leading provider of diagnostic information services that supports clinical decision-making for patients, physicians and healthcare organizations. The company operates a network of clinical laboratories and patient service centers that perform a broad range of laboratory tests and diagnostic assays used in routine care, disease diagnosis, monitoring and screening.

Its services span core clinical laboratory testing, anatomic pathology, molecular and genomic diagnostics, infectious disease testing and toxicology.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.